Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease

Area of Science:

• Cardiology
• Oncology
• Pharmacology

Background:

• Cardiovascular events are a leading cause of death in cancer patients, often linked to anticancer therapies.
• Developing cardioprotective strategies is crucial for managing cancer treatment side effects.

Purpose of the Study:

• To review mechanisms of anticancer therapy-induced cardiotoxicity.
• To explore the potential cardioprotective mechanisms of statins.
• To discuss current research and future directions for statins in preventing cancer treatment-related cardiovascular disease.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of proposed mechanisms of cardiotoxicity and statin action.
• Synthesis of existing evidence on statin efficacy in various anticancer treatment models.

Main Results:

• Statins exhibit antioxidative, anti-inflammatory, antifibrotic, and endothelial protective properties relevant to cardiotoxicity.
• Clinical evidence supports statins in chemotherapy-induced cardiotoxicity; preclinical data show benefits against radiotherapy and trastuzumab-induced damage.
• Statins show promise in mitigating damage from immune checkpoint inhibitors and CAR-T cell therapy, though direct evidence for the latter is limited.

Conclusions:

• Statins hold significant potential for preventing cardiovascular complications associated with diverse anticancer therapies.
• Further clinical trials are warranted to establish the efficacy of statins in mitigating cardiotoxicity from novel cancer treatments.
• Investigating statins for cardiovascular disease prevention in cancer patients undergoing treatment is a critical future research direction.